AustraliaHealth

Island Pharmaceuticals (ASX:ILA) expands US Army partnership to advance a critical Galidesivir dose optimisation study.

Sigma Healthcare (ASX:SIG) is reportedly mulling a cross-border bid for British health and beauty giant Boots.

Integral Diagnostics (ASX:IDX) will initiate an independent audit following recent media reports alleging inappropriate billing practices in Western Australia.

Imugene (ASX:IMU) announced that the US FDA has granted Fast Track Designation to its novel therapy, azer-cel.

OncoSil Medical (ASX:OSL) enters the final stage of FDA review for its OncoSil device HDE application.

LTR Pharma (ASX:LTP) has secured a foothold in the United States by executing a binding term sheet with Shed Holdings.

Vitura Health (ASX:VIT) announced the immediate appointment of Tom Howitt as interim CFO.

Island Pharmaceuticals (ASX:ILA) launched a comprehensive GMP manufacturing campaign for antiviral candidate Galidesivir.

Pro Medicus (ASX:PME) has secured a major five-year, $16 million contract renewal with The Ohio State University Wexner Medical Centre.

Cynata Therapeutics (ASX:CYP) has received a positive opinion from the European Medicines Agency’s paediatric committee.

Firebrick Pharma (ASX:FRE) said its patent covering the composition of Nasodine nasal spray has been granted in New Zealand.

Cancer diagnostics company Pacific Edge (ASX:PEB) has finalised a NZ$36.1 million capital raising campaign.